News & Press Releases
News & Press Releases
News & Press Releases
Here you’ll find official announcements, company updates, and press releases from Psyence Biomed. This page provides verified, up-to-date information on our progress, partnerships, clinical milestones, and corporate developments.
We believe in keeping our stakeholders informed and engaged with clear and timely communication. Whether it’s news about our scientific breakthroughs, regulatory updates, or leadership commentary, this is your trusted source for all formal communications from Psyence Biomed.
All press releases are archived for reference and can be accessed at any time. For journalists or media professionals, please reach out to our team through the Contact page for further information or interviews.
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives.
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Psyence BioMed has begun its NPX-5 psilocybin trial, dosing the first patient in a Phase IIb study targeting adjustment disorder in palliative care.
Psyence BioMed Positioned as World’s only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
Psyence BioMed reinforces its vertically integrated pharmaceutical platform through its investment in PsyLabs, securing GMP manufacturing, compound supply, and long term commercial infrastructure.
News and Press Releases
Here you’ll find official announcements, company updates, and press releases from Psyence Biomed. This page provides verified, up-to-date information on our progress, partnerships, clinical milestones, and corporate developments.
We believe in keeping our stakeholders informed and engaged with clear and timely communication. Whether it’s news about our scientific breakthroughs, regulatory updates, or leadership commentary, this is your trusted source for all formal communications from Psyence Biomed.
All press releases are archived for reference and can be accessed at any time. For journalists or media professionals, please reach out to our team through the Contact page for further information or interviews.
